{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T22:33:02Z","timestamp":1790548382455,"version":"4.1.0"},"reference-count":115,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T00:00:00Z","timestamp":1713830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T00:00:00Z","timestamp":1713830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s10787-024-01477-0","type":"journal-article","created":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T19:06:01Z","timestamp":1713899161000},"page":"1791-1804","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Neuroinflammation and the role of epigenetic-based therapies for Huntington\u2019s disease management: the new paradigm"],"prefix":"10.1007","volume":"32","author":[{"given":"Pooja","family":"Temgire","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richmond","family":"Arthur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7978-1043","authenticated-orcid":false,"given":"Puneet","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,23]]},"reference":[{"issue":"2","key":"1477_CR1","first-page":"90","volume":"16","author":"A Abdanipour","year":"2012","unstructured":"Abdanipour A, Schluesener HJ, Tiraihi T (2012) Effects of valproic acid, a histone deacetylase inhibitor, on improvement of locomotor function in rat spinal cord injury based on epigenetic science. Iran Biomed J 16(2):90\u2013100","journal-title":"Iran Biomed J"},{"issue":"4","key":"1477_CR2","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s00210-022-02350-z","volume":"396","author":"R Arthur","year":"2022","unstructured":"Arthur R, Navik U, Kumar P (2022) Repurposing artemisinins as neuroprotective agents: a focus on the PI3k\/Akt signalling pathway. Naunyn Schmiedebergs Arch Pharmacol 396(4):593\u2013605","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"4","key":"1477_CR3","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s12017-021-08660-4","volume":"23","author":"KV Athira","year":"2021","unstructured":"Athira KV, Sadanandan P, Chakravarty S (2021) Repurposing vorinostat for the treatment of disorders affecting brain. Neuromolecular Med 23(4):449\u2013465","journal-title":"Neuromolecular Med"},{"issue":"2","key":"1477_CR4","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.bbrc.2017.05.040","volume":"488","author":"JJ Ban","year":"2017","unstructured":"Ban JJ et al (2017) MicroRNA-27a reduces mutant huntingtin aggregation in an in vitro model of Huntington\u2019s disease. Biochem Biophys Res Commun 488(2):316\u2013321","journal-title":"Biochem Biophys Res Commun"},{"key":"1477_CR5","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/978-3-319-53889-1_15","volume":"978","author":"S Bassi","year":"2017","unstructured":"Bassi S et al (2017) Epigenetics of Huntington\u2019s disease. Adv Exp Med Biol 978:277\u2013299","journal-title":"Adv Exp Med Biol"},{"issue":"9","key":"1477_CR6","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.tins.2018.05.005","volume":"41","author":"A Berson","year":"2018","unstructured":"Berson A et al (2018) Epigenetic regulation in neurodegenerative diseases. Trends Neurosci 41(9):587\u2013598","journal-title":"Trends Neurosci"},{"issue":"9","key":"1477_CR7","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1093\/hmg\/ddv006","volume":"24","author":"M Biagioli","year":"2015","unstructured":"Biagioli M et al (2015) Htt CAG repeat expansion confers pleiotropic gains of mutant huntingtin function in chromatin regulation. Hum Mol Genet 24(9):2442\u20132457","journal-title":"Hum Mol Genet"},{"key":"1477_CR8","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13072-015-0016-6","volume":"8","author":"A Breiling","year":"2015","unstructured":"Breiling A, Lyko F (2015) Epigenetic regulatory functions of DNA modifications: 5-methylcytosine and beyond. Epigenetics Chromatin 8:24","journal-title":"Epigenetics Chromatin"},{"key":"1477_CR9","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1146\/annurev.genet.032608.103928","volume":"43","author":"EI Campos","year":"2009","unstructured":"Campos EI, Reinberg D (2009) Histones: annotating chromatin. Annu Rev Genet 43:559\u2013599","journal-title":"Annu Rev Genet"},{"issue":"10","key":"1477_CR10","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/nrd.2018.133","volume":"17","author":"NS Caron","year":"2018","unstructured":"Caron NS, Dorsey ER, Hayden MR (2018) Therapeutic approaches to Huntington disease: from the bench to the clinic. Nat Rev Drug Discov 17(10):729\u2013750","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"1477_CR11","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s13023-017-0742-x","volume":"12","author":"KH Chang","year":"2017","unstructured":"Chang KH, Wu YR, Chen CM (2017) Down-regulation of miR-9* in the peripheral leukocytes of Huntington\u2019s disease patients. Orphanet J Rare Dis 12(1):185","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"1477_CR12","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.ajhg.2013.05.025","volume":"93","author":"PH Cheng","year":"2013","unstructured":"Cheng PH et al (2013) miR-196a ameliorates phenotypes of Huntington disease in cell, transgenic mouse, and induced pluripotent stem cell models. Am J Hum Genet 93(2):306\u2013312","journal-title":"Am J Hum Genet"},{"key":"1477_CR13","doi-asserted-by":"publisher","first-page":"243","DOI":"10.3389\/fncel.2018.00243","volume":"12","author":"M Cheray","year":"2018","unstructured":"Cheray M, Joseph B (2018) Epigenetics control microglia plasticity. Front Cell Neurosci 12:243","journal-title":"Front Cell Neurosci"},{"issue":"4","key":"1477_CR14","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.pneurobio.2010.01.002","volume":"90","author":"L Chouliaras","year":"2010","unstructured":"Chouliaras L et al (2010) Epigenetic regulation in the pathophysiology of Alzheimer\u2019s disease. Prog Neurobiol 90(4):498\u2013510","journal-title":"Prog Neurobiol"},{"issue":"3","key":"1477_CR15","doi-asserted-by":"publisher","first-page":"185","DOI":"10.2174\/2211536605666151204111323","volume":"4","author":"S Das","year":"2015","unstructured":"Das S, Bhattacharyya NP (2015) Heat shock factor 1-regulated miRNAs can target huntingtin and suppress aggregates of mutant huntingtin. Microrna 4(3):185\u2013193","journal-title":"Microrna"},{"issue":"2","key":"1477_CR16","doi-asserted-by":"publisher","first-page":"86","DOI":"10.2174\/2211536604666150713105606","volume":"4","author":"E Das","year":"2015","unstructured":"Das E, Jana NR, Bhattacharyya NP (2015) Delayed cell cycle progression in STHdh(Q111)\/Hdh(Q111) cells, a cell model for Huntington\u2019s disease mediated by microRNA-19a, microRNA-146a and microRNA-432. Microrna 4(2):86\u2013100","journal-title":"Microrna"},{"issue":"10","key":"1477_CR17","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1093\/hmg\/ddw076","volume":"25","author":"RA De Souza","year":"2016","unstructured":"De Souza RA et al (2016) DNA methylation profiling in human Huntington\u2019s disease brain. Hum Mol Genet 25(10):2013\u20132030","journal-title":"Hum Mol Genet"},{"key":"1477_CR18","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.phrs.2016.05.005","volume":"108","author":"C D\u00edez-Planelles","year":"2016","unstructured":"D\u00edez-Planelles C et al (2016) Circulating microRNAs in Huntington\u2019s disease: emerging mediators in metabolic impairment. Pharmacol Res 108:102\u2013110","journal-title":"Pharmacol Res"},{"issue":"13","key":"1477_CR19","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.1523\/JNEUROSCI.0037-07.2007","volume":"27","author":"JP Dompierre","year":"2007","unstructured":"Dompierre JP et al (2007) Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington\u2019s disease by increasing tubulin acetylation. J Neurosci 27(13):3571\u20133583","journal-title":"J Neurosci"},{"key":"1477_CR20","doi-asserted-by":"publisher","first-page":"705348","DOI":"10.3389\/fncel.2021.705348","volume":"15","author":"X Dong","year":"2021","unstructured":"Dong X, Cong S (2021) MicroRNAs in Huntington\u2019s disease: diagnostic biomarkers or therapeutic agents? Front Cell Neurosci 15:705348","journal-title":"Front Cell Neurosci"},{"issue":"2","key":"1477_CR21","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ab.2010.01.010","volume":"399","author":"EN Ebbel","year":"2010","unstructured":"Ebbel EN et al (2010) Identification of phenylbutyrate-generated metabolites in Huntington disease patients using parallel liquid chromatography\/electrochemical array\/mass spectrometry and off-line tandem mass spectrometry. Anal Biochem 399(2):152\u2013161","journal-title":"Anal Biochem"},{"issue":"23","key":"1477_CR22","doi-asserted-by":"publisher","first-page":"15173","DOI":"10.3390\/ijms232315173","volume":"23","author":"A Farag\u00f3","year":"2022","unstructured":"Farag\u00f3 A et al (2022) Acetylation state of lysine 14 of histone H33 affects mutant huntingtin induced pathogenesis. Int J Mol Sci 23(23):15173","journal-title":"Int J Mol Sci"},{"issue":"4","key":"1477_CR23","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/nn.2514","volume":"13","author":"J Feng","year":"2010","unstructured":"Feng J et al (2010) Dnmt1 and Dnmt3a maintain DNA methylation and regulate synaptic function in adult forebrain neurons. Nat Neurosci 13(4):423\u2013430","journal-title":"Nat Neurosci"},{"issue":"46","key":"1477_CR24","doi-asserted-by":"publisher","first-page":"10335","DOI":"10.1523\/JNEUROSCI.2599-04.2004","volume":"24","author":"RJ Ferrante","year":"2004","unstructured":"Ferrante RJ et al (2004) Chemotherapy for the brain: the antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington\u2019s disease. J Neurosci 24(46):10335\u201310342","journal-title":"J Neurosci"},{"issue":"1","key":"1477_CR25","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1074\/jbc.M410210200","volume":"280","author":"G Gardian","year":"2005","unstructured":"Gardian G et al (2005) Neuroprotective effects of phenylbutyrate in the N171\u201382Q transgenic mouse model of Huntington\u2019s disease. J Biol Chem 280(1):556\u2013563","journal-title":"J Biol Chem"},{"key":"1477_CR26","unstructured":"Ghosh P, Saadat A (2021) Neurodegeneration and epigenetics: a review. Neurologia (Engl Ed)"},{"key":"1477_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-319-71779-1_1","volume":"1049","author":"R Ghosh","year":"2018","unstructured":"Ghosh R, Tabrizi SJ (2018) Clinical features of Huntington\u2019s disease. Adv Exp Med Biol 1049:1\u201328","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"1477_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/JHD-140134","volume":"4","author":"KE Glajch","year":"2015","unstructured":"Glajch KE, Sadri-Vakili G (2015) Epigenetic mechanisms involved in Huntington\u2019s disease pathogenesis. J Huntingtons Dis 4(1):1\u201315","journal-title":"J Huntingtons Dis"},{"issue":"6","key":"1477_CR29","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/j.1755-5949.2010.00184.x","volume":"16","author":"SG Gray","year":"2010","unstructured":"Gray SG (2010) Targeting histone deacetylases for the treatment of Huntington\u2019s disease. CNS Neurosci Ther 16(6):348\u2013361","journal-title":"CNS Neurosci Ther"},{"issue":"11","key":"1477_CR30","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1016\/j.bbadis.2015.08.012","volume":"1852","author":"P Guedes-Dias","year":"2015","unstructured":"Guedes-Dias P et al (2015) HDAC6 inhibition induces mitochondrial fusion, autophagic flux and reduces diffuse mutant huntingtin in striatal neurons. Biochim Biophys Acta 1852(11):2484\u20132493","journal-title":"Biochim Biophys Acta"},{"issue":"10","key":"1477_CR31","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1038\/nn.2900","volume":"14","author":"JU Guo","year":"2011","unstructured":"Guo JU et al (2011) Neuronal activity modifies the DNA methylation landscape in the adult brain. Nat Neurosci 14(10):1345\u20131351","journal-title":"Nat Neurosci"},{"issue":"9","key":"1477_CR32","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.7150\/thno.18813","volume":"7","author":"LS Her","year":"2017","unstructured":"Her LS et al (2017) miR-196a enhances neuronal morphology through suppressing RANBP10 to provide neuroprotection in Huntington\u2019s disease. Theranostics 7(9):2452\u20132462","journal-title":"Theranostics"},{"issue":"7","key":"1477_CR33","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.18632\/aging.101005","volume":"8","author":"S Horvath","year":"2016","unstructured":"Horvath S et al (2016) Huntington\u2019s disease accelerates epigenetic aging of human brain and disrupts DNA methylation levels. Aging (Albany NY) 8(7):1485\u20131512","journal-title":"Aging (Albany NY)"},{"issue":"4","key":"1477_CR34","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1136\/gutjnl-2012-304219","volume":"63","author":"K Hur","year":"2014","unstructured":"Hur K et al (2014) Hypomethylation of long interspersed nuclear element-1 (LINE-1) leads to activation of proto-oncogenes in human colorectal cancer metastasis. Gut 63(4):635\u2013646","journal-title":"Gut"},{"key":"1477_CR35","doi-asserted-by":"publisher","first-page":"105074","DOI":"10.1016\/j.neuint.2021.105074","volume":"148","author":"JW Hyeon","year":"2021","unstructured":"Hyeon JW, Kim AH, Yano H (2021) Epigenetic regulation in Huntington\u2019s disease. Neurochem Int 148:105074","journal-title":"Neurochem Int"},{"issue":"4","key":"1477_CR36","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1097\/00001756-200303240-00007","volume":"14","author":"S Igarashi","year":"2003","unstructured":"Igarashi S et al (2003) Inducible PC12 cell model of Huntington\u2019s disease shows toxicity and decreased histone acetylation. NeuroReport 14(4):565\u2013568","journal-title":"NeuroReport"},{"issue":"1","key":"1477_CR37","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1080\/01616412.2016.1251711","volume":"39","author":"MT Islam","year":"2017","unstructured":"Islam MT (2017) Oxidative stress and mitochondrial dysfunction-linked neurodegenerative disorders. Neurol Res 39(1):73\u201382","journal-title":"Neurol Res"},{"issue":"1","key":"1477_CR38","doi-asserted-by":"publisher","first-page":"E56","DOI":"10.1073\/pnas.1415195112","volume":"112","author":"H Jia","year":"2015","unstructured":"Jia H et al (2015) HDAC inhibition imparts beneficial transgenerational effects in Huntington\u2019s disease mice via altered DNA and histone methylation. Proc Natl Acad Sci U S A 112(1):E56\u2013E64","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"1477_CR39","doi-asserted-by":"publisher","first-page":"e0152498","DOI":"10.1371\/journal.pone.0152498","volume":"11","author":"H Jia","year":"2016","unstructured":"Jia H et al (2016) The effects of pharmacological inhibition of histone deacetylase 3 (HDAC3) in Huntington\u2019s disease mice. PLoS One 11(3):e0152498","journal-title":"PLoS One"},{"issue":"7","key":"1477_CR40","doi-asserted-by":"publisher","first-page":"a024240","DOI":"10.1101\/cshperspect.a024240","volume":"7","author":"M Jimenez-Sanchez","year":"2017","unstructured":"Jimenez-Sanchez M et al (2017) Huntington\u2019s disease: mechanisms of pathogenesis and therapeutic strategies. Cold Spring Harb Perspect Med 7(7):a024240","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"8","key":"1477_CR41","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.biopsych.2020.11.009","volume":"89","author":"EB Johnson","year":"2021","unstructured":"Johnson EB et al (2021) Dynamics of cortical degeneration over a decade in Huntington\u2019s disease. Biol Psychiatry 89(8):807\u2013816","journal-title":"Biol Psychiatry"},{"issue":"1","key":"1477_CR42","doi-asserted-by":"publisher","first-page":"e54222","DOI":"10.1371\/journal.pone.0054222","volume":"8","author":"A Jovicic","year":"2013","unstructured":"Jovicic A et al (2013) MicroRNA-22 (miR-22) overexpression is neuroprotective via general anti-apoptotic effects and may also target specific Huntington\u2019s disease-related mechanisms. PLoS One 8(1):e54222","journal-title":"PLoS One"},{"issue":"6","key":"1477_CR43","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.3390\/biomedicines10061432","volume":"10","author":"A Jurcau","year":"2022","unstructured":"Jurcau A (2022) Molecular pathophysiological mechanisms in Huntington\u2019s disease. Biomedicines 10(6):1432","journal-title":"Biomedicines"},{"key":"1477_CR44","doi-asserted-by":"publisher","first-page":"101664","DOI":"10.1016\/j.pneurobio.2019.101664","volume":"182","author":"CA Ju\u017awik","year":"2019","unstructured":"Ju\u017awik CA et al (2019) microRNA dysregulation in neurodegenerative diseases: a systematic review. Prog Neurobiol 182:101664","journal-title":"Prog Neurobiol"},{"key":"1477_CR45","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3389\/fcell.2014.00049","volume":"2","author":"RR Kanherkar","year":"2014","unstructured":"Kanherkar RR, Bhatia-Dey N, Csoka AB (2014) Epigenetics across the human lifespan. Front Cell Dev Biol 2:49","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"1477_CR46","first-page":"90","volume":"11","author":"G Kaur","year":"2022","unstructured":"Kaur G et al (2022) DNA methylation: a promising approach in management of Alzheimer\u2019s disease and other neurodegenerative disorders. Biology (Basel) 11(1):90","journal-title":"Biology (Basel)"},{"issue":"1","key":"1477_CR47","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/cga.12043","volume":"54","author":"Y Kawahara","year":"2014","unstructured":"Kawahara Y (2014) Human diseases caused by germline and somatic abnormalities in microRNA and microRNA-related genes. Congenit Anom (Kyoto) 54(1):12\u201321","journal-title":"Congenit Anom (Kyoto)"},{"issue":"22","key":"1477_CR48","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1212\/WNL.0b013e318294b304","volume":"80","author":"A Killoran","year":"2013","unstructured":"Killoran A et al (2013) Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS. Neurology 80(22):2022\u20132027","journal-title":"Neurology"},{"issue":"16","key":"1477_CR49","doi-asserted-by":"publisher","first-page":"8363","DOI":"10.3390\/ijms22168363","volume":"22","author":"A Kim","year":"2021","unstructured":"Kim A et al (2021) New avenues for the treatment of Huntington\u2019s disease. Int J Mol Sci 22(16):8363","journal-title":"Int J Mol Sci"},{"issue":"7","key":"1477_CR50","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/jhg.2013.66","volume":"58","author":"H Kimura","year":"2013","unstructured":"Kimura H (2013) Histone modifications for human epigenome analysis. J Hum Genet 58(7):439\u2013445","journal-title":"J Hum Genet"},{"issue":"1","key":"1477_CR51","doi-asserted-by":"publisher","first-page":"158","DOI":"10.2174\/1570159X19666210609160017","volume":"20","author":"V Kumar","year":"2022","unstructured":"Kumar V et al (2022) Understanding the role of histone deacetylase and their inhibitors in neurodegenerative disorders: current targets and future perspective. Curr Neuropharmacol 20(1):158\u2013178","journal-title":"Curr Neuropharmacol"},{"issue":"9","key":"1477_CR52","doi-asserted-by":"publisher","first-page":"e0162788","DOI":"10.1371\/journal.pone.0162788","volume":"11","author":"T Kunkanjanawan","year":"2016","unstructured":"Kunkanjanawan T et al (2016) miR-196a ameliorates cytotoxicity and cellular phenotype in transgenic Huntington\u2019s disease monkey neural cells. PLoS One 11(9):e0162788","journal-title":"PLoS One"},{"issue":"1","key":"1477_CR53","first-page":"3","volume":"5","author":"S Kurdyukov","year":"2016","unstructured":"Kurdyukov S, Bullock M (2016) DNA methylation analysis: choosing the right method. Biology (Basel) 5(1):3","journal-title":"Biology (Basel)"},{"issue":"3","key":"1477_CR54","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/nrg2732","volume":"11","author":"PW Laird","year":"2010","unstructured":"Laird PW (2010) Principles and challenges of genomewide DNA methylation analysis. Nat Rev Genet 11(3):191\u2013203","journal-title":"Nat Rev Genet"},{"key":"1477_CR55","doi-asserted-by":"publisher","first-page":"42875","DOI":"10.1038\/srep42875","volume":"7","author":"S Le Gras","year":"2017","unstructured":"Le Gras S et al (2017) Altered enhancer transcription underlies Huntington\u2019s disease striatal transcriptional signature. Sci Rep 7:42875","journal-title":"Sci Rep"},{"issue":"11","key":"1477_CR56","doi-asserted-by":"publisher","first-page":"e1001442","DOI":"10.1371\/journal.pbio.1001442","volume":"10","author":"G Le Martelot","year":"2012","unstructured":"Le Martelot G et al (2012) Genome-wide RNA polymerase II profiles and RNA accumulation reveal kinetics of transcription and associated epigenetic changes during diurnal cycles. PLoS Biol 10(11):e1001442","journal-title":"PLoS Biol"},{"issue":"12","key":"1477_CR57","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1093\/hmg\/ddn067","volume":"17","author":"J Lee","year":"2008","unstructured":"Lee J et al (2008) Monoallele deletion of CBP leads to pericentromeric heterochromatin condensation through ESET expression and histone H3 (K9) methylation. Hum Mol Genet 17(12):1774\u20131782","journal-title":"Hum Mol Genet"},{"issue":"4","key":"1477_CR58","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1007\/s13311-013-0206-5","volume":"10","author":"J Lee","year":"2013","unstructured":"Lee J et al (2013) Epigenetic mechanisms of neurodegeneration in Huntington\u2019s disease. Neurotherapeutics 10(4):664\u2013676","journal-title":"Neurotherapeutics"},{"issue":"7638","key":"1477_CR59","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature21029","volume":"541","author":"SA Liddelow","year":"2017","unstructured":"Liddelow SA et al (2017) Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541(7638):481\u2013487","journal-title":"Nature"},{"issue":"13","key":"1477_CR60","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.4161\/cc.20864","volume":"11","author":"IM Love","year":"2012","unstructured":"Love IM et al (2012) The histone acetyltransferase PCAF regulates p21 transcription through stress-induced acetylation of histone H3. Cell Cycle 11(13):2458\u20132466","journal-title":"Cell Cycle"},{"issue":"1","key":"1477_CR61","doi-asserted-by":"publisher","first-page":"4529","DOI":"10.1038\/s41467-020-18255-5","volume":"11","author":"AT Lu","year":"2020","unstructured":"Lu AT et al (2020) DNA methylation study of Huntington\u2019s disease and motor progression in patients and in animal models. Nat Commun 11(1):4529","journal-title":"Nat Commun"},{"issue":"2","key":"1477_CR62","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3233\/JAD-2010-100303","volume":"21","author":"SC Marques","year":"2010","unstructured":"Marques SC et al (2010) Alzheimer\u2019s disease: the quest to understand complexity. J Alzheimers Dis 21(2):373\u2013383","journal-title":"J Alzheimers Dis"},{"issue":"20","key":"1477_CR63","doi-asserted-by":"publisher","first-page":"7219","DOI":"10.1093\/nar\/gkq575","volume":"38","author":"E Mart\u00ed","year":"2010","unstructured":"Mart\u00ed E et al (2010) A myriad of miRNA variants in control and Huntington\u2019s disease brain regions detected by massively parallel sequencing. Nucleic Acids Res 38(20):7219\u20137235","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"1477_CR64","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1093\/hmg\/ddt499","volume":"23","author":"KN McFarland","year":"2014","unstructured":"McFarland KN et al (2014) MeCP2: a novel huntingtin interactor. Hum Mol Genet 23(4):1036\u20131044","journal-title":"Hum Mol Genet"},{"issue":"10","key":"1477_CR65","doi-asserted-by":"publisher","first-page":"7717","DOI":"10.1007\/s12035-018-0951-x","volume":"55","author":"J Mingardi","year":"2018","unstructured":"Mingardi J et al (2018) miRNA editing: new insights into the fast control of gene expression in health and disease. Mol Neurobiol 55(10):7717\u20137727","journal-title":"Mol Neurobiol"},{"issue":"2","key":"1477_CR66","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1007\/s12640-014-9458-z","volume":"26","author":"J Mishra","year":"2014","unstructured":"Mishra J, Chaudhary T, Kumar A (2014) Rosiglitazone synergizes the neuroprotective effects of valproic acid against quinolinic acid-induced neurotoxicity in rats: targeting PPAR\u03b3 and HDAC pathways. Neurotox Res 26(2):130\u2013151","journal-title":"Neurotox Res"},{"issue":"1","key":"1477_CR67","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1055\/s-0034-1397344","volume":"35","author":"AM Mohr","year":"2015","unstructured":"Mohr AM, Mott JL (2015) Overview of microRNA biology. Semin Liver Dis 35(1):3\u201311","journal-title":"Semin Liver Dis"},{"key":"1477_CR68","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3389\/fneur.2013.00127","volume":"4","author":"L Moumn\u00e9","year":"2013","unstructured":"Moumn\u00e9 L, Betuing S, Caboche J (2013) Multiple aspects of gene dysregulation in Huntington\u2019s disease. Front Neurol 4:127","journal-title":"Front Neurol"},{"key":"1477_CR69","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/B978-0-12-801893-4.00001-8","volume":"144","author":"MA Nance","year":"2017","unstructured":"Nance MA (2017) Genetics of Huntington disease. Handb Clin Neurol 144:3\u201314","journal-title":"Handb Clin Neurol"},{"issue":"6","key":"1477_CR70","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1073\/pnas.1221292110","volume":"110","author":"CW Ng","year":"2013","unstructured":"Ng CW et al (2013) Extensive changes in DNA methylation are associated with expression of mutant huntingtin. Proc Natl Acad Sci U S A 110(6):2354\u20132359","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"53","key":"1477_CR71","doi-asserted-by":"publisher","first-page":"14341","DOI":"10.1523\/JNEUROSCI.2390-08.2008","volume":"28","author":"AN Packer","year":"2008","unstructured":"Packer AN et al (2008) The bifunctional microRNA miR-9\/miR-9* regulates REST and CoREST and is downregulated in Huntington\u2019s disease. J Neurosci 28(53):14341\u201314346","journal-title":"J Neurosci"},{"issue":"4","key":"1477_CR72","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s40520-019-01430-0","volume":"33","author":"C Pagiatakis","year":"2021","unstructured":"Pagiatakis C et al (2021) Epigenetics of aging and disease: a brief overview. Aging Clin Exp Res 33(4):737\u2013745","journal-title":"Aging Clin Exp Res"},{"key":"1477_CR73","doi-asserted-by":"publisher","first-page":"31022","DOI":"10.1038\/srep31022","volume":"6","author":"Y Pan","year":"2016","unstructured":"Pan Y et al (2016) Inhibition of DNA methyltransferases blocks mutant huntingtin-induced neurotoxicity. Sci Rep 6:31022","journal-title":"Sci Rep"},{"issue":"1","key":"1477_CR74","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1369\/0022155413506582","volume":"62","author":"S Parbin","year":"2014","unstructured":"Parbin S et al (2014) Histone deacetylases: a saga of perturbed acetylation homeostasis in cancer. J Histochem Cytochem 62(1):11\u201333","journal-title":"J Histochem Cytochem"},{"key":"1477_CR75","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.neuroscience.2017.02.002","volume":"348","author":"X Qi","year":"2017","unstructured":"Qi X et al (2017) Long non-coding RNA SNHG14 promotes microglia activation by regulating miR-145-5p\/PLA2G4A in cerebral infarction. Neuroscience 348:98\u2013106","journal-title":"Neuroscience"},{"key":"1477_CR76","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s12038-020-00099-2","volume":"45","author":"S Ramazi","year":"2020","unstructured":"Ramazi S, Allahverdi A, Zahiri J (2020) Evaluation of post-translational modifications in histone proteins: a review on histone modification defects in developmental and neurological disorders. J Biosci 45:135","journal-title":"J Biosci"},{"issue":"11","key":"1477_CR77","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1080\/15384101.2015.1033595","volume":"14","author":"T Ratovitski","year":"2015","unstructured":"Ratovitski T et al (2015) PRMT5-mediated symmetric arginine dimethylation is attenuated by mutant huntingtin and is impaired in Huntington\u2019s disease (HD). Cell Cycle 14(11):1716\u20131729","journal-title":"Cell Cycle"},{"issue":"11","key":"1477_CR78","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1111\/bph.12854","volume":"172","author":"M Remely","year":"2015","unstructured":"Remely M et al (2015) Therapeutic perspectives of epigenetically active nutrients. Br J Pharmacol 172(11):2756\u20132768","journal-title":"Br J Pharmacol"},{"issue":"50","key":"1477_CR79","doi-asserted-by":"publisher","first-page":"19176","DOI":"10.1073\/pnas.0606373103","volume":"103","author":"H Ryu","year":"2006","unstructured":"Ryu H et al (2006) ESET\/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington\u2019s disease. Proc Natl Acad Sci U S A 103(50):19176\u201319181","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"1477_CR80","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.2174\/1570159X19666211201094608","volume":"20","author":"J Saba","year":"2022","unstructured":"Saba J et al (2022) Neuroinflammation in Huntington\u2019s disease: a starring role for astrocyte and microglia. Curr Neuropharmacol 20(6):1116\u20131143","journal-title":"Curr Neuropharmacol"},{"issue":"4","key":"1477_CR81","doi-asserted-by":"publisher","first-page":"403","DOI":"10.2174\/156720506778249407","volume":"3","author":"G Sadri-Vakili","year":"2006","unstructured":"Sadri-Vakili G, Cha JH (2006) Histone deacetylase inhibitors: a novel therapeutic approach to Huntington\u2019s disease (complex mechanism of neuronal death). Curr Alzheimer Res 3(4):403\u2013408","journal-title":"Curr Alzheimer Res"},{"issue":"4","key":"1477_CR82","doi-asserted-by":"publisher","first-page":"232","DOI":"10.3390\/brainsci10040232","volume":"10","author":"LN Schaffert","year":"2020","unstructured":"Schaffert LN, Carter WG (2020) Do post-translational modifications influence protein aggregation in neurodegenerative diseases: a systematic review. Brain Sci 10(4):232","journal-title":"Brain Sci"},{"key":"1477_CR83","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.euroneuro.2020.01.015","volume":"33","author":"E Schueller","year":"2020","unstructured":"Schueller E et al (2020) Dysregulation of histone acetylation pathways in hippocampus and frontal cortex of Alzheimer\u2019s disease patients. Eur Neuropsychopharmacol 33:101\u2013116","journal-title":"Eur Neuropsychopharmacol"},{"key":"1477_CR84","doi-asserted-by":"publisher","first-page":"537","DOI":"10.3389\/fphar.2020.00537","volume":"11","author":"S Shukla","year":"2020","unstructured":"Shukla S, Tekwani BL (2020) Histone deacetylases inhibitors in neurodegenerative diseases, neuroprotection and neuronal differentiation. Front Pharmacol 11:537","journal-title":"Front Pharmacol"},{"issue":"37","key":"1477_CR85","doi-asserted-by":"publisher","first-page":"E8765","DOI":"10.1073\/pnas.1807962115","volume":"115","author":"FA Siebzehnr\u00fcbl","year":"2018","unstructured":"Siebzehnr\u00fcbl FA et al (2018) Early postnatal behavioral, cellular, and molecular changes in models of Huntington disease are reversible by HDAC inhibition. Proc Natl Acad Sci U S A 115(37):E8765\u2013E8774","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"1477_CR86","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s12017-012-8183-0","volume":"14","author":"M Sinha","year":"2012","unstructured":"Sinha M, Mukhopadhyay S, Bhattacharyya NP (2012) Mechanism(s) of alteration of micro RNA expressions in Huntington\u2019s disease and their possible contributions to the observed cellular and molecular dysfunctions in the disease. Neuromolecular Med 14(4):221\u2013243","journal-title":"Neuromolecular Med"},{"issue":"8","key":"1477_CR87","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/s10822-020-00304-2","volume":"34","author":"Y Sixto-L\u00f3pez","year":"2020","unstructured":"Sixto-L\u00f3pez Y, Bello M, Correa-Basurto J (2020) Exploring the inhibitory activity of valproic acid against the HDAC family using an MMGBSA approach. J Comput Aided Mol Des 34(8):857\u2013878","journal-title":"J Comput Aided Mol Des"},{"issue":"2","key":"1477_CR88","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1021\/ac0489420","volume":"77","author":"L Song","year":"2005","unstructured":"Song L et al (2005) Specific method for the determination of genomic DNA methylation by liquid chromatography-electrospray ionization tandem mass spectrometry. Anal Chem 77(2):504\u2013510","journal-title":"Anal Chem"},{"key":"1477_CR89","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/978-1-61779-328-8_32","volume":"793","author":"E Soragni","year":"2011","unstructured":"Soragni E et al (2011) Evaluation of histone deacetylase inhibitors as therapeutics for neurodegenerative diseases. Methods Mol Biol 793:495\u2013508","journal-title":"Methods Mol Biol"},{"issue":"10","key":"1477_CR90","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1093\/hmg\/ddm064","volume":"16","author":"EC Stack","year":"2007","unstructured":"Stack EC et al (2007) Modulation of nucleosome dynamics in Huntington\u2019s disease. Hum Mol Genet 16(10):1164\u20131175","journal-title":"Hum Mol Genet"},{"key":"1477_CR91","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.semcdb.2019.05.004","volume":"94","author":"CS Subhramanyam","year":"2019","unstructured":"Subhramanyam CS et al (2019) Microglia-mediated neuroinflammation in neurodegenerative diseases. Semin Cell Dev Biol 94:112\u2013120","journal-title":"Semin Cell Dev Biol"},{"issue":"4","key":"1477_CR92","doi-asserted-by":"publisher","first-page":"277","DOI":"10.2174\/187152809789352249","volume":"8","author":"S Sugama","year":"2009","unstructured":"Sugama S et al (2009) Possible roles of microglial cells for neurotoxicity in clinical neurodegenerative diseases and experimental animal models. Inflamm Allergy Drug Targets 8(4):277\u2013284","journal-title":"Inflamm Allergy Drug Targets"},{"issue":"3","key":"1477_CR93","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1111\/bcp.12512","volume":"79","author":"SD S\u00fcssmuth","year":"2015","unstructured":"S\u00fcssmuth SD et al (2015) An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington\u2019s disease. Br J Clin Pharmacol 79(3):465\u2013476","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"1477_CR94","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2174\/2211536607666180827111633","volume":"8","author":"M Tafrihi","year":"2019","unstructured":"Tafrihi M, Hasheminasab E (2019) MiRNAs: biology, biogenesis, their web-based tools, and databases. Microrna 8(1):4\u201327","journal-title":"Microrna"},{"issue":"3","key":"1477_CR95","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1007\/s12035-014-8803-9","volume":"51","author":"L Tan","year":"2015","unstructured":"Tan L, Yu JT, Tan L (2015) Causes and consequences of microRNA dysregulation in neurodegenerative diseases. Mol Neurobiol 51(3):1249\u20131262","journal-title":"Mol Neurobiol"},{"issue":"1","key":"1477_CR96","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.gpb.2016.09.002","volume":"15","author":"A Tapias","year":"2017","unstructured":"Tapias A, Wang ZQ (2017) Lysine acetylation and deacetylation in brain development and neuropathies. Genomics Proteomics Bioinformatics 15(1):19\u201336","journal-title":"Genomics Proteomics Bioinformatics"},{"issue":"11","key":"1477_CR97","doi-asserted-by":"publisher","first-page":"5938","DOI":"10.3390\/ijms23115938","volume":"23","author":"DM Teleanu","year":"2022","unstructured":"Teleanu DM et al (2022) An overview of oxidative stress, neuroinflammation, and neurodegenerative diseases. Int J Mol Sci 23(11):5938","journal-title":"Int J Mol Sci"},{"issue":"40","key":"1477_CR98","doi-asserted-by":"publisher","first-page":"15564","DOI":"10.1073\/pnas.0804249105","volume":"105","author":"EA Thomas","year":"2008","unstructured":"Thomas EA et al (2008) The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington\u2019s disease transgenic mice. Proc Natl Acad Sci U S A 105(40):15564\u201315569","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"1477_CR99","doi-asserted-by":"publisher","first-page":"5660","DOI":"10.18632\/oncotarget.13924","volume":"8","author":"LM Valor","year":"2017","unstructured":"Valor LM (2017) Understanding histone deacetylation in Huntington\u2019s disease. Oncotarget 8(4):5660\u20135661","journal-title":"Oncotarget"},{"key":"1477_CR100","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.neuropharm.2013.10.025","volume":"80","author":"LM Valor","year":"2014","unstructured":"Valor LM, Guiretti D (2014) What\u2019s wrong with epigenetics in Huntington\u2019s disease? Neuropharmacology 80:103\u2013114","journal-title":"Neuropharmacology"},{"issue":"32","key":"1477_CR101","doi-asserted-by":"publisher","first-page":"E3027","DOI":"10.1073\/pnas.1311323110","volume":"110","author":"M Vashishtha","year":"2013","unstructured":"Vashishtha M et al (2013) Targeting H3K4 trimethylation in Huntington disease. Proc Natl Acad Sci U S A 110(32):E3027\u2013E3036","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"1477_CR102","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s12017-013-8219-0","volume":"15","author":"I Villar-Men\u00e9ndez","year":"2013","unstructured":"Villar-Men\u00e9ndez I et al (2013) Increased 5-methylcytosine and decreased 5-hydroxymethylcytosine levels are associated with reduced striatal A2AR levels in Huntington\u2019s disease. Neuromolecular Med 15(2):295\u2013309","journal-title":"Neuromolecular Med"},{"issue":"18","key":"1477_CR103","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.1093\/hmg\/ddt214","volume":"22","author":"F Wang","year":"2013","unstructured":"Wang F et al (2013) Genome-wide loss of 5-hmC is a novel epigenetic feature of Huntington\u2019s disease. Hum Mol Genet 22(18):3641\u20133653","journal-title":"Hum Mol Genet"},{"issue":"4","key":"1477_CR104","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.bbrc.2017.05.005","volume":"487","author":"Y Wen","year":"2017","unstructured":"Wen Y, Yu Y, Fu X (2017) LncRNA Gm4419 contributes to OGD\/R injury of cerebral microglial cells via I\u03baB phosphorylation and NF-\u03baB activation. Biochem Biophys Res Commun 487(4):923\u2013929","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"1477_CR105","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/nrneurol.2013.23","volume":"9","author":"H Wood","year":"2013","unstructured":"Wood H (2013) Neurodegenerative disease: altered DNA methylation and RNA splicing could be key mechanisms in Huntington disease. Nat Rev Neurol 9(3):119","journal-title":"Nat Rev Neurol"},{"issue":"8","key":"1477_CR106","doi-asserted-by":"publisher","first-page":"4411","DOI":"10.1073\/pnas.1919197117","volume":"117","author":"S Yang","year":"2020","unstructured":"Yang S et al (2020) Lack of RAN-mediated toxicity in Huntington\u2019s disease knock-in mice. Proc Natl Acad Sci U S A 117(8):4411\u20134417","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1477_CR107","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/978-3-319-57379-3_6","volume":"987","author":"C Yapijakis","year":"2017","unstructured":"Yapijakis C (2017) Huntington disease: genetics, prevention, and therapy approaches. Adv Exp Med Biol 987:55\u201365","journal-title":"Adv Exp Med Biol"},{"key":"1477_CR108","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.brainres.2013.02.012","volume":"1504","author":"HH Yeh","year":"2013","unstructured":"Yeh HH et al (2013) Histone deacetylase class II and acetylated core histone immunohistochemistry in human brains with Huntington\u2019s disease. Brain Res 1504:16\u201324","journal-title":"Brain Res"},{"key":"1477_CR109","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-4939-7601-0_1","volume":"1733","author":"SY Ying","year":"2018","unstructured":"Ying SY, Chang DC, Lin SL (2018) The microRNA. Methods Mol Biol 1733:1\u201325","journal-title":"Methods Mol Biol"},{"issue":"21","key":"1477_CR110","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.3390\/cells11213439","volume":"11","author":"S Younesian","year":"2022","unstructured":"Younesian S et al (2022) The DNA methylation in neurological diseases. Cells 11(21):3439","journal-title":"Cells"},{"key":"1477_CR111","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13024-016-0094-3","volume":"11","author":"Y Zhou","year":"2016","unstructured":"Zhou Y et al (2016) MicroRNA-7 targets Nod-like receptor protein 3 inflammasome to modulate neuroinflammation in the pathogenesis of Parkinson\u2019s disease. Mol Neurodegener 11:28","journal-title":"Mol Neurodegener"},{"issue":"3","key":"1477_CR112","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/epigenomes4030015","volume":"4","author":"G Zimmer-Bensch","year":"2020","unstructured":"Zimmer-Bensch G (2020) Epigenomic remodeling in Huntington\u2019s disease-master or servant? Epigenomes 4(3):15","journal-title":"Epigenomes"},{"issue":"7","key":"1477_CR113","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.4103\/1673-5374.235029","volume":"13","author":"N Zsindely","year":"2018","unstructured":"Zsindely N, Bodai L (2018) Histone methylation in Huntington\u2019s disease: are bivalent promoters the critical targets? Neural Regen Res 13(7):1191\u20131192","journal-title":"Neural Regen Res"},{"issue":"23","key":"1477_CR114","doi-asserted-by":"publisher","first-page":"12736","DOI":"10.3390\/ijms222312736","volume":"22","author":"N Zsindely","year":"2021","unstructured":"Zsindely N, Si\u00e1gi F, Bodai L (2021) DNA methylation in Huntington\u2019s disease. Int J Mol Sci 22(23):12736","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1477_CR115","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/ng1219","volume":"35","author":"C Zuccato","year":"2003","unstructured":"Zuccato C et al (2003) Huntingtin interacts with REST\/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat Genet 35(1):76\u201383","journal-title":"Nat Genet"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-024-01477-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-024-01477-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-024-01477-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T15:08:31Z","timestamp":1716995311000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-024-01477-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,23]]},"references-count":115,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["1477"],"URL":"https:\/\/doi.org\/10.1007\/s10787-024-01477-0","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,23]]},"assertion":[{"value":"20 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There are no relevant financial or non-financial interests to disclose for the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}